PinCell srl

PinCell srl is an Italian biotechnology company focused on dermatology, specifically the development of first-in-class anti-inflammatory therapies for skin diseases with high unmet medical need. According to its official website, PinCell is a pre-clinical stage biotech company whose research targets novel pathological pathways involved in the pathomechanism of different dermatological disorders, with particular emphasis on "orphan diseases" of the skin. The company positions itself at the intersection of academic dermatological research and drug development, aiming to create treatments where few or no approved options currently exist. PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by Prof. Carlo Pincelli and Dr. Alessandra Marconi. Both founders are also described as co-inventors, reflecting the company's origin in patented academic research. Carlo Pincelli is Professor of Dermatology with extensive clinical and research experience, served as Chief of the Laboratory of Cutaneous Biology at the University of Modena and Reggio Emilia, and has held leadership roles in European dermatology organizations. Alessandra Marconi is Professor of Dermatological Applications of Medical Biotechnologies at the same university and a biologist and clinical pathologist with long experience in basic and clinical dermatology research. The company's management team includes Antonino Amato as Chairman and CEO, Carlo Pincelli as CMO, Co-Founder and Co-Inventor, Roberta Lotti as Project Manager and Senior Researcher, and Brydon Bennett as CSO. Antonino Amato has a medical degree and prior managerial experience in the biotech and pharmaceutical industry, including roles at Sigma-Tau and BetaGlue Technologies SpA. PinCell's therapeutic focus is on orphan skin diseases, an area characterized by high unmet medical need and limited commercial competition. Its stated mission is to develop first-in-class treatments by targeting novel pathways involved in disease mechanisms. The company is headquartered in Milan, Italy, and operates as a private, pre-clinical stage enterprise. Its pipeline and programs are based on patented drug candidates originating from the founders' research, with at least one inventor patent noted as having reached Phase IIb in development.

PinCell srl was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia. The company was established by Prof. Carlo Pincelli and Dr. Alessandra Marconi, both professors at the university and co-inventors of the underlying drug patents. This origin places PinCell within a broader wave of Italian academic spin-offs created to translate university research in dermatology and biotechnology into therapeutic candidates. From its inception, PinCell's mission has been to develop first-in-class treatments for orphan skin diseases by targeting novel pathways involved in disease pathomechanisms. The founders brought substantial academic and clinical credentials: Carlo Pincelli is a Professor of Dermatology with decades of clinical and research experience, served as Chief of the Laboratory of Cutaneous Biology at the University of Modena and Reggio Emilia, and has held leadership positions in European dermatology societies. Alessandra Marconi is a Professor of Dermatological Applications of Medical Biotechnologies, a biologist and clinical pathologist with extensive research experience in dermatology and diagnostics. The company has remained a pre-clinical stage biotech, focused on research and development rather than marketed products. Its intellectual property portfolio derives from the founders' patented inventions, with at least one inventor patent noted as having reached Phase IIb in development. Over time, PinCell has built a management team combining scientific founders with industry-experienced executives. Antonino Amato serves as Chairman and CEO, bringing prior managerial experience from the biotech and pharmaceutical sector, including roles at Sigma-Tau and BetaGlue Technologies SpA. Roberta Lotti serves as Project Manager and Senior Researcher, and Brydon Bennett as Chief Scientific Officer. PinCell is headquartered in Milan, Italy, and operates as a private company. Its therapeutic focus remains on orphan dermatological diseases, an area of high unmet medical need where the company aims to leverage novel pathological pathways to create first-in-class anti-inflammatory therapies.

• 2008

  PinCell founded in October as an academic spin-off of the University of Modena and Reggio Emilia by Prof. Carlo Pincelli and Dr. Alessandra Marconi.

• Company established as a pre-clinical stage biotech focused on orphan skin diseases.

• Antonino Amato appointed Chairman & CEO.

Pre-clinical stage dermatology biotech developing first-in-class treatments for orphan skin diseases with high unmet medical need.

• First-in-class anti-inflammatory therapies for orphan skin diseases

  Pre-clinical drug candidates targeting novel pathological pathways in dermatological disorders.

1. 1Home - PinCellpincell.it
2. 2About us - PinCellpincell.it
3. 3Founders - PinCellpincell.it
4. 4Board of Directors - PinCellpincell.it
5. 5PinCell srl (Italy) - Wikidatawikidata.org